- cafead   Jun 30, 2022 at 11:22: AM
via Battered by a struggling stock market and inflation, the biotech industry has been looking for multiple sources of financing, including the potential sale of net operating loss carryforwards. There has also been speculation that big pharma and its millions upon millions of dollars set aside for M&A may come to the rescue.
article source
article source